Effect of Potent P2Y₁₂ Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis

Table 2

Patients’ characteristics of included RCTs.

Study	Age (years)	Male (%)	ACS (%)	PCI (%)	Smoker (%)	Diabetes mellitus (%)	Hypertension (%)	Prior MI (%)
DISPERSE-2 [11]	63.0±11.6	63.7	100.0	42.0	N/A	24.8	N/A	26.0
PLATO [1]	62.2 (53.0, 70.0)	74.8	99.8	76.8	35.9	23.2	65.4	17.0
PHILO [12]	67.0±11.0	76.4	100.0	84.6	38.5	34.7	74.3	8.0
JUMBO-TIMI26 [13]	59.2±9.03	77.0	40.0	100.0	28.4	25.0	N/A	N/A
TRITON-TIMI 38 [2]	60.9±11.3	74.1	100.0	100.0	38.0	23.0	64.0	18.0
Ge et al. [14]	60.8±11.1	74.8	100.0	100.0	N/A	N/A	N/A	N/A
TRILOGY ACS [15]	65.7±11.0	60.9	100.0	0	39.9	37.9	82.0	42.8
TRIGGER PCI [16]	66.1±8.4	72.6	0	100.0	14.4	41.8	88.9	27.4
ETAMI [17]	N/A	72.6	100.0	87.1	74.2	19.4	54.8	8.1

N/A: not available, DISPERSE-2: dose confirmation study assessing anti-platelet effects of AZD6140 vs. clopidogrel in non-ST-segment elevation myocardial infarction-2, PLATO: platelet inhibition and patient outcomes, PHILO: ticagrelor vs. clopidogrel in Japanese, Korean, and Taiwanese patients with acute coronary syndrome, JUMBO-TIMI26: joint utilization of medications to block platelets optimally-thrombolysis in myocardial infarction 26, TRITON-TIMI 38: trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction, TRILOGY ACS: the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes, TRIGGER PCI: testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel, ETAMI: early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction ACS: acute coronary syndrome, PCI: percutaneous coronary intervention, MI: myocardial infarction.
Age is presented as either mean ± standard deviation or median (interquartile range) when available.